Rubén Rodríguez-Cano1, Ana López-Durán1, Elena Fernández del Río2, Carmela Martínez-Vispo1, Úrsula Martínez1, Elisardo Becoña1. 1. Smoking Cessation and Addictive Disorders Unit, Faculty of Psychology, Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain. 2. Smoking Cessation and Addictive Disorders Unit, Faculty of Psychology, Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain; Department of Psychology and Sociology, Faculty of Social Sciences and Work, University of Zaragoza, Spain.
Abstract
BACKGROUND: The relationship between tobacco and depressive symptoms has been examined. However, there is little information on the evolution of these symptoms when an individual quits. The aim of this study was to analyze the evolution of depressive symptoms over time (pre-, post-treatment, 1-, 3-, 6-, and 12-months follow-up) in relation to smoking status 12 months after having received a psychological treatment for smoking cessation. METHOD: The sample was made up of 242 adults who received cognitive-behavioral treatment for smoking cessation (64.4% women; mean age=41.71 years). The BDI-II was used to assess depressive symptomatology. Participants were classified into three groups according to smoking status at 12-months follow-up (abstainers, relapsers, and smokers). RESULTS: There were no significant differences in depressive symptoms among the three groups at pretreatment. At the end of treatment, abstainers and relapsers presented less depressive symptomatology than smokers. At follow-up, abstainers continued to present less depressive symptomatology than smokers, whereas in relapsers, symptoms began to increase as the relapses occurred. Regarding the evolution of depressive symptomatology, the abstainer and relapser groups showed a significant reduction at the end of treatment. Only in the group of abstainers did the decrease continue during 12 months follow-up. LIMITATIONS: The decrease of the initial sample size from 562 to 242 participants. Variables such as self-esteem and self-efficacy were not assessed. CONCLUSIONS: Smoking cessation is associated with a decrease in depressive symptomatology, that is maintained over time. In contrast, relapse is associated with an increase of such symptoms. These findings signify the potential importance of addressing depressive symptomatology in smoking cessation treatment.
BACKGROUND: The relationship between tobacco and depressive symptoms has been examined. However, there is little information on the evolution of these symptoms when an individual quits. The aim of this study was to analyze the evolution of depressive symptoms over time (pre-, post-treatment, 1-, 3-, 6-, and 12-months follow-up) in relation to smoking status 12 months after having received a psychological treatment for smoking cessation. METHOD: The sample was made up of 242 adults who received cognitive-behavioral treatment for smoking cessation (64.4% women; mean age=41.71 years). The BDI-II was used to assess depressive symptomatology. Participants were classified into three groups according to smoking status at 12-months follow-up (abstainers, relapsers, and smokers). RESULTS: There were no significant differences in depressive symptoms among the three groups at pretreatment. At the end of treatment, abstainers and relapsers presented less depressive symptomatology than smokers. At follow-up, abstainers continued to present less depressive symptomatology than smokers, whereas in relapsers, symptoms began to increase as the relapses occurred. Regarding the evolution of depressive symptomatology, the abstainer and relapser groups showed a significant reduction at the end of treatment. Only in the group of abstainers did the decrease continue during 12 months follow-up. LIMITATIONS: The decrease of the initial sample size from 562 to 242 participants. Variables such as self-esteem and self-efficacy were not assessed. CONCLUSIONS: Smoking cessation is associated with a decrease in depressive symptomatology, that is maintained over time. In contrast, relapse is associated with an increase of such symptoms. These findings signify the potential importance of addressing depressive symptomatology in smoking cessation treatment.
Authors: D Galan; B I Perry; V Warrier; C C Davidson; O Stupart; D Easton; G M Khandaker; G K Murray Journal: Sci Rep Date: 2022-09-03 Impact factor: 4.996
Authors: Lenka Stepankova; Eva Kralikova; Kamila Zvolska; Alexandra Pankova; Petra Ovesna; Milan Blaha; Leonie S Brose Journal: Ann Behav Med Date: 2017-06
Authors: Elisardo Becoña; Carmela Martínez-Vispo; Carmen Senra; Ana López-Durán; Rubén Rodríguez-Cano; Elena Fernández Del Río Journal: BMC Psychiatry Date: 2017-04-08 Impact factor: 3.630
Authors: Carmela Martínez-Vispo; Rubén Rodríguez-Cano; Ana López-Durán; Carmen Senra; Elena Fernández Del Río; Elisardo Becoña Journal: PLoS One Date: 2019-04-08 Impact factor: 3.240
Authors: Evelyn Arana-Chicas; Ana Paula Cupertino; Kathy Goggin; Kimber P Richter; Kari J Harris; Delwyn Catley Journal: Subst Use Misuse Date: 2021-06-15 Impact factor: 2.362